Breeding and Application of Japonica CMS Line Yangfujing 7A with Fine Grain Quality, Disease Resistance and High Combining Ability in Rice

Yangfujing 7A, derived from the cross between Xu 9201A and Yangfujing 7 and its successive backcrosses, is a BT-type japonica CMS line developed by the Agricultural Institute of Riparian Region of Jiangsu Province. It shows good integrat- ed characteristics, stable male sterility, good flowering habits, high out crossing rate, strong disease resistance, fine grain quality （reaching the 1st class of national standards for fine quality rice） and high combining ability. In 2012, it was technically identified in Jiangsu Province. Its F1 hybrid combination Tongyoujingl （Yangfujing 7 A/R98）, showing high yield and good grain quality, was registered and released to commercial production by Jiangsu Crop Variety Appraisal Committee in 2013.

Anticancer activity of Tephrosia purpurea and Ficus religiosa using MCF 7 cell lines

Objective:To investigate anticancer activity of different fractions of Tephrosia purpurea[TP] （Sharapunkha,Fabaceae） and Ficus religiosa[FR]（Peepal,Moraceae）.Methods:The fractions of TP and FR were prepared and tested for in vitro anticancer activity using human MCF 7 cell line by trypan blue exclusion method.Results:The result showed that among all these fractions of TPI.TPIII.FRI and FRIII showed better anticancer activity compared to other fractions.The IC50 value for TPI（152.4μM）,TPIII（158.71μM）.FRI（160.3μM） and for FRIII（222.7μM） was observed.Conclusions:The present study shows anticancer potential of TP and FR fractions in MCF 7 cell line.

Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin

Objective:To evaluate of hesperidin to overcome resistance of doxorubicin in MCF-7 resistant doxorubicin cells(MCF-7/Dox)in cytotoxicity apoptosis and P-glycoprotein(Pgp)expression in combination with doxorubicin.Methods:The cytotoxic properties.50%inhibition concentration(IC_(50))and its combination with doxorubicin in MCF-7 cell lines resistant to doxorubicin(MCF-7/Dox)cells were determined using MTT assay.Apoptosis induction was examined by double staining assay using ethidium bromide-acridine orange.Immunocytochemistry assay was performed to determine the level and localization of Pgp.Results:Single treatment of hesperidin showed cytotoxic activity on MCF-7/Dox cells with IC_(50)value of 11μmol/L.Thus,combination treatment from hesperidin and doxorubicin showed addictive and antagonist effect(CI>1.0).Hesperidin did not increase the apoptotic induction,but decreased the Pgp expressions level when combined with doxorubicin in low concentration.Conclusions:Hesperidin has cytotoxic effect on MCF-7/Dox cells with IC_(50)of 11μmol/L.Hesperidin did not increased the apoptotic induction combined with doxorubicin.Cochemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression.

SOX7靶向ERK1/2/PD-L1通路抑制结直肠癌血管生成

目的探讨性别决定区Y框蛋白7(SOX7)对结直肠癌血管生成的影响及潜在作用机制。方法应用免疫荧光检测结直肠癌患者组织样本中SOX7表达水平,之后通过裸鼠、转染SOX7 mimic的人结直肠癌细胞系SW480细胞和人脐静脉内皮细胞(HUVEC)共培养进一步研究。用Western-blot验证SOX7与ERK1/2/PD-L1对结直肠癌细胞的相关蛋白表达的影响。用CCK8检测SOX7与ERK1/2/PD-L1对HUVEC增殖的影响。通过体外内皮细胞成管实验测定SOX7与ERK1/2/PD-L1对肿瘤血管生成的影响。结果SOX7在人结直肠癌组织中表达被抑制(P<0.01),同时SOX7的过表达抑制了小鼠体内肿瘤生长(P<0.01)。SW480细胞中SOX7的过表达抑制了ERK1/2、c-Jun的表达,并在ERK1/2的激动剂Senkyunolide I的作用下上调了SW480细胞的ERK1/2、c-Jun蛋白表达(P<0.01),逆转了SOX7对SW480细胞中ERK1/2、c-Jun蛋白表达的影响(P<0.01)。HUVEC中SOX7抑制了PD-L1、V-EGFR2、p-PI3K、HIF-1α的蛋白表达,Senkyunolide I上调了HUVEC的PD-L1、V-EGFR2、p-PI3K、HIF-1α的蛋白表达,并逆转了SOX7对HUVEC中上述相关蛋白表达的影响(P<0.01)。PD-1/PD-L1 Inhibitor 3抑制了PD-L1、V-EGFR2、p-PI3K、HIF-1α的蛋白表达,SOX7过表达在PD-1/PD-L1 Inhibitor 3的影响下并没有表现出抑制作用。CCK8实验结果显示SOX7过表达显著抑制了HUVEC的增殖能力,Senkyunolide I作用下的两组HUVEC增殖能力较SOX7 NC组与SOX7 mimic组明显上升,PD-1/PD-L1 Inhibitor 3作用下的两组HUVEC增殖能力较SOX7 NC组与SOX7 mimic组明显下降,以上均有明显统计学差异(P<0.01)。成管实验结果显示SOX7过表达抑制了HUVEC的血管生成,Senkyunolide I强烈加速了血管生成,而PD-1/PD-L1 Inhibitor 3血管生成则被显著抑制,以上均有明显统计学差异(P<0.01)。结论SOX7通过ERK1/2/PD-L1通路抑制结直肠肿瘤的增殖和血管生成,SOX7可能是晚期CRC患者临床治疗中潜在的抗血管生成靶点。

Anticancer property of sediment actinomycetes against MCF-7 and MDA-MB-231 cell lines

ObjectiveTo investigate the anticancer property of marine sediment actinomycetes against two different breast cancer cell lines.MethodsIn vitro anticancer activity was carried out against breast (MCF-7 and MDA-MB-231) cancer cell lines. Partial sequences of the 16s rRNA gene, phylogenetic tree construction, multiple sequence analysis and secondary structure analysis were also carried out with the actinomycetes isolates.ResultsOf the selected five actinomycete isolates, ACT01 and ACT02 showed the IC50 value with (10.13±0.92) and (22.34±5.82) μg/mL concentrations, respectively for MCF-7 cell line at 48 h, but ACT01 showed the minimum (18.54±2.49 μg/mL) level of IC50 value with MDA-MB-231 cell line. Further, the 16s rRNA partial sequences of ACT01, ACT02, ACT03, ACT04 and ACT05 isolates were also deposited in NCBI data bank with the accession numbers of GQ478246, GQ478247, GQ478248, GQ478249 and GQ478250, respectively. The phylogenetic tree analysis showed that, the isolates of ACT02 and ACT03 were represented in group I and III, respectively, but ACT01 and ACT02 were represented in group II. The multiple sequence alignment of the actinomycete isolates showed that, the maximum identical conserved regions were identified with the nucleotide regions of 125 to 221st base pairs, 65 to 119th base pairs and 55, 48 and 31st base pairs. Secondary structure prediction of the 16s rRNA showed that, the maximum free energy was consumed with ACT03 isolate (-45.4 kkal/mol) and the minimum free energy was consumed with ACT04 isolate (?7.6 kkal/mol).ConclusionsThe actinomycete isolates of ACT01 and ACT02 (GQ478246 and GQ478247) which are isolated from sediment sample can be further used as anticancer agents against breast cancer cell lines.

STUDY OF ENHANCED IMMUNOGENECITY OF B7-1 GENE TRANSFECTED HUMAN HELA CELL LINE

This work was supposed by CMB (No. 96—635) This is one of papers of the special issue on gene therapy research (Chin J Cancer Res Vol. 9 No. 4 December, 1997). Although cervical carcinoma cells may express the human papillomavirus protein E6 and E7, they fail to induce an effective specific cytotoxic T lymphocyte response. Recent studies suggest that expression of CD 80 (B7 1) on tumor cells is effective to induce antitumor immune responses. 1,2 In our study, CD 80 gene was transfected into human Hela cell line with a CD 80 expression plasmid (B7 1 +pcDNA 3) by electroporation, then the immunogenecity of the modified Hela cell was tested in TLMC (tumor lymphocyte mixed culture) system. Thymidine lymphocyte proliferation assays showed that the response of human peripheral blood lymphocytes (PBLS) to CD 80 positive Hela cells demonstrated a substantial increase in cell proliferation compared to the response to control cells. Cocultivation of allogeneic PBLs with CD 80 positive tumor cells for three days can induce an increased secretion of IL 2. Our results demonstrate an immunostimulatory effect of CD 80 expression on cervical cancer cells, which provides a basis for the development of a therapeutic tumor vaccine.

REVERSION OF MULTIDRUG RESISTANCE IN THE P-GLYCOPROTEIN POSITIVE BREAST CANCER CELL LINE(MCF-7/ADR) BY INTRODUCTION OF HAMMERHEAD RIBOZYME

A hammerhead ribozyme which site-specifically cleaved the GUC position in canon 880 of the mdr1 mRNA was designed. The target site was chosen between the two ATP binding sites, which may be important for the function of the P-Gp as an ATP-dependent pump. A DNA sequence encoding the ribozyme gene was then incorporated into a eukaryotic expression vector (pH Apr-1 neo) and transfected into the breast cancer cell line MCF-7/Adr, which is resistant to adriamycin and expresses the MDR phenotype. The ribozyme was stably expressed in the cell line by the RNA dot blotting assay. The result of Northern blot assay showed that the expressed ribozyme could decrease the level of mdrl mRNA expression by 83. 5 %; and the expressed ribozyme could inhibite the formation of p-glycoprotein detected by immuno- cy-tochemistry assay and could reduce the cell’s resistance to adrimycin; this means that the resistant cells were 1 000-fold more resistant than the parental cell line(MCF-7), whereas those cell clones that showed ribozyme expression were only 6-fold more resistant than the parental cell line. These results show that a potentially useful tool is at hand which may inactivate MDR1 mRNA and revert the multidrug resistance phenotype.

Studies on mechanism of cis9,trans11-CLA and trans10,cis12-CLA inducing apoptosis of human breast cancer cell line MCF-7

Objective： The aim of the study was to explore the activities of cis9, trans11-CLA （C9, t11-CLA） and transl0, cis12-CLA （t10, c12-CLA） inhibiting tumor, and investigate their relationships with PPARy and apoptotic proteins, and mechanism of anti-cancer. Methods： The inhibitory rate, cell growth curve and apoptotic morphological observation of MCF-7 cells were obtained by MTT assay, trypan blue staining and Hoechst33342 fluorescence staining. The apoptotic rate and cell cycle were detected with flow cytometry. Transcriptional level of genes was detected with RT-PCR semi-quantitative method, and Western blot was performed to detect proteins levels. Results： The two CLA isomers could reduce cell proliferation （P 〈 0.05）, increase apoptotic rate （P 〈 0.05）, and increase obviously the transcriptional and protein levels of PPARy （P 〈 0.01）. The synchronism and correlation between the effects of CLA to PPARy and apoptotic proteins Bax, Bcl-2, Caspase 3 changes were found with the dose- and time-dependent manners. There was cooperative relation between the levels of PPARy and the rates of Bax/Bcl-2, Caspase 3 （small fragment） by experiments of PPARy inhibitor GW9662 and ligand Rosiglitazone. Conclusion： The apoptotic pathway of PPARy-Bcl-2-Caspase 3 signaling was found. The C9, t11-CLA and tl0, c12-CLA could inhibit MCF-7 cell proliferation and promote apoptosis via activating PPARy-Bcl-2-Caspase 3 pathway. CLA may be a kind of activator of PPARv.

Effects of 4-(3-Chloro-Benzyl)-6,7-Dimethoxy-Quinazoline on Kinetics of P120-Catenin and Periplakin in Human Buccal Mucosa Squamous Carcinoma Cell Line

In order to detect molecular markers for the epidermal growth factor inhibitor 4-(3-chloro-benzyl)- 6,7-dimethoxy-quinazoline (tyrphostin), we investigated the kinetics of p120-catenin and periplakin in the human buccal mucosa squamous cancer cell line BICR 10 treated with 3 nM tyrphostin. Growth of BICR 10 cells was inhibited by treatment with tyrphostin. Although changes were not observed in the expression of EGFR and p120-catenin, expression of Akt, Src and periplakin in BICR 10 treated with 3 nM tyrphostin tended to decrease. In addition, phosphorylation of EGFR, Akt and Src was inhibited by treatment with tyrphostin. On immunocytochemical staining, immunoreactions with phosphorylated EGFR, phosphorylated Akt and phosphorylated p120-catenin were weak in BICR 10 treated with tyrphostin. There was a slight immunocy to chemical reaction to periplakin in BICR 10 cells induced by tyrphostin. In conclusion, the decrease in phosphorylation in EGFR and p120-catenin by tyrphostin, following the decrease in Src or Akt phosphorylation, may inhibit expression of several growth factors associated with the proliferation and migration of cancer cells.

C_(4)F_(7)N/CO_(2)/O_(2)混合气体近区故障开断性能研究

六氟化硫(SF_(6))气体因其具有优良的绝缘与灭弧性能,现已广泛应用于电力设备中,但由于其具有强温室效应,随着全球变暖问题的日益严重,急需寻找能够替代SF_(6)的新型环保气体。其中,全氟异丁腈(C_(4)F_(7)N)具有优异的绝缘性能,有良好的工程应用前景,然而目前尚无针对C_(4)F_(7)N/CO_(2)/O_(2)混合气体断路器的近区故障开断特性研究。文中针对126 k V/3 150 A/40 k A柱式C_(4)F_(7)N混合气体断路器的近区故障开断性能进行研究,对比了断路器充入C_(4)F_(7)N/CO_(2)/O_(2)混合气体、CO_(2)/O_(2)混合气体和SF_(6)气体在不同电流过零时电流下降率(di/dt)下的近区故障开断性能。L90近区故障开断实验结果显示,在相同条件下SF_(6)气体表现出最佳的开断性能,能够在较宽的燃弧时间窗口内稳定开断实验电流。0.7 MPa的C_(4)F_(7)N/CO_(2)/O_(2)混合气体和CO_(2)/O_(2)混合气体在di/dt=12 A/μs条件下的开断表现与0.5 MPa的SF_(6)气体在di/dt=20 A/μs条件下的开断表现接近。基于实验结果提出了灭弧室结构的改进方案,并进行了实验验证文中的研究为C_(4)F_(7)N混合气体断路器的开发与设计提供了参考。

Construction of Cox7a2 fluorescent vector and its effect on cytochrome C oxidase activity in mouse Sertoli cell line TM4

Objective To construct Cox7a2 fluorescent vector and study its effect on cytochrome C oxidase ( COX) activity in mouse Sertoli cell line TM4. Methods The coding region of CoxTa2 was amplified from mouse Sertoli cell line TM4 by RT-PCR. PCR product was

青蒿素和青蒿琥酯对人乳腺癌MCF-7细胞的体外抑制作用比较研究

目的 对比研究青蒿素及其衍生物青蒿琥酯对人乳腺癌 MCF- 7细胞增殖的影响并探讨其作用机制。方法采用体外培养的人乳腺癌 MCF- 7细胞株 ,利用 SRB法测定青蒿素和青蒿琥酯对 MCF- 7细胞增殖的影响 ,FCM法测定细胞周期的变化 ,亚 G1 期含量测定和 DAPI荧光染色法观察细胞凋亡。结果 10 μmol/L 青蒿素和 1μmol/L青蒿琥酯能明显改变 MCF- 7细胞的细胞周期 ,使 S期细胞显著减少 ,G0 +G1 期细胞明显增加。青蒿素对 MCF-7细胞增殖仅有微弱抑制作用 ,但其衍生物青蒿琥酯却有显著的抑制作用 ,IC50 为 0 .31μmol/L。同样 ,1μmol/L 青蒿琥酯引起 MCF- 7细胞的凋亡和直接的细胞毒作用明显强于 10μm ol/L青蒿素的作用。结论 体外研究表明 ,对肿瘤细胞增殖的抑制青蒿琥酯比青蒿素作用强。

苦参碱对MCF-7细胞Fas、VEGF及端粒酶活性的影响

目的研究苦参碱对人乳腺癌MCF-7细胞Fas、VEGF及端粒酶活性的影响。方法体外培养人乳腺癌MCF-7细胞,随机分组,实验组细胞加入苦参碱溶液,对照组或阴性对照组细胞加入等量培养液,阳性对照组细胞加入端粒酶抑制剂莪术油。采用倒置显微镜下观察细胞形态学变化;TRAP-ELISA法检测端粒酶活性;免疫细胞化学法检测MCF-7细胞中Fas、VEGF蛋白表达情况。结果苦参碱对乳腺癌细胞有明显的生长抑制作用和促凋亡作用;不同浓度苦参碱处理MCF-7细胞24、48、72h后,端粒酶活性随苦参碱浓度增加和作用时间延长而逐渐下降,呈剂量—效应正相关和时间—效应正相关;苦参碱能够上调MCF-7细胞Fas蛋白表达和下调MCF-7细胞VEGF蛋白表达。结论苦参碱对MCF-7细胞具有明显的生长抑制作用和促凋亡作用,可能是通过上调Fas蛋白表达、抑制端粒酶活性诱导乳腺癌细胞凋亡及通过下调VEGF蛋白表达,抑制肿瘤血管形成等实现的。

龙麦20小麦品种中7+8~*亚基和17+18亚基近等基因系间的品质差异

【目的】确定高分子麦谷蛋白亚基17+18和7+8*间的遗传差异。【方法】利用生化标记和选择性回交(5次)的方法将拥有超量表达的Bx7亚基的加拿大超强筋小麦品种Glenlea的7+8*亚基转移到了小麦品种龙麦20亚基组成为1,17+18,5+10的近等基因系(NILs)中,获得了龙麦20的17+18亚基和7+8*亚基的近等基因系。2005年这对近等基因系被种植在黑龙江农业科学院育种研究所的试验地里,试验设计采用随机取组,6次重复。【结果】品质分析结果表明,7+8*亚基类型的龙麦20与17+18亚基龙麦20类型相比,面粉蛋白质含量提高5%(P=0.012)、干面筋含量增加4%(P=0.018)、湿面筋/干面筋降低2%(P=0.043)、沉降值提高10%(P=0.013)、形成时间提高13%(P=0.258)、稳定时间提高256%(P=0.029)、断裂时间提高86%(P=0.020)、软化度降低35%(P=0.007)。【结论】7+8*亚基对面筋强度有较大的正向影响。

人参皂甙Rh_2逆转P-gp介导的MCF-7/ADM多药耐药性的基础研究

目的:研究人参皂甙Rh2在逆转多药耐药(MDR)方面的作用及其机理。方法:Rh2和阿霉素单独或联合作用于MCF-7及MCF-7/ADM细胞,应用MTT法确定各组细胞的IC50。罗丹明123加入各组细胞,流式细胞仪分析Rh2和维拉帕米抑制罗丹明123外排的情况。RT-PCR检测各组mdr1 mRNA表达量及流式细胞仪检测各组P-gp的表达情况。结果:Rh2可以显著降低MCF-7/ADM的ADM IC50(P<0.05),对MCF-7细胞没有影响。Rh2和维拉帕米可以增加MCF-7/ADM细胞内罗丹明123荧光表达率(P<0.05),Rh2比维拉帕米抑制罗丹明123外排作用更强。在MCF-7细胞内Rh2和维拉帕米无此作用。Rh2对MCF-7/ADM细胞mdr1 mRNA表达及P-gp表达没有影响。结论:人参皂甙Rh2可以有效逆转P-gp介导的人乳腺癌细胞耐药细胞系MCF-7/ADM的耐药性。

植物雌激素对乳腺癌细胞MCF-7增殖的影响

目的 : 探讨植物雌激素大豆异黄酮 (genistein,GS)和玉米赤霉烯酮 (zearalenone,ZEA)对乳腺癌细胞株 MCF- 7增殖的影响。方法 : 雌激素依赖性 MCF- 7细胞在 DMEM培养液(含小牛血清 1 0 % )中采用开放式单层贴壁培养 ,于加受试物前 5 d将细胞用 PBS洗涤后改为无酚红高糖 DMEM(含 5 %经活性碳 -葡聚糖苷处理的胎牛血清 ,CDT- FBS)培养 ,实验设溶剂对照、雌激素对照、抗雌激素对照及两种受试物各四个剂量组 ,采用噻唑蓝 (MTT)法、3H- Td R掺入法及流式细胞术对 MCF- 7细胞的增殖情况进行分析。结果 : 与溶剂对照组相比较 ,GS(96μmol/ L,2 4h)可明显抑制 MCF- 7细胞增殖和细胞 DNA合成 ,并将细胞周期阻滞在 G2 / M;8μmol/ L GS处理96 h也能产生类似的抑制效果。 96 nmol/ L ZEA处理 2 4 h可明显促进 MCF- 7细胞增殖和细胞DNA合成 ,并将细胞周期由 G0 / G1向 S期推进 ,提高细胞分裂增殖指数。结论 : ZEA和 GS均属环境雌激素 ,但对乳腺癌细胞 MCF- 7增殖产生的影响不同 ,ZEA可促进 MCF- 7增殖 ,而 GS能够抑制 MCF- 7细胞的增殖 ,即

Landsat 7图像快速几何校正方法研究

Landsat7采用双向扫描的方式,由于扫描非线性及卫星姿态和轨道的波动,使得建立卫星视线的计算量增大。引入一种求视线的快速方法,将图像上的扭曲分解为标称扫描镜及卫星运动引起的和7个偏离标称运动的微扰量引起的两个部分,详细分析了各个微扰量造成的影响,建立了一个新的视线求解方程。最后用实际的数据验证了方法的速度和精度。

环境雌激素对乳腺癌细胞株MCF-7凋亡作用的影响

[目的 ]通过观察对 壬基酚 (nonylphenol ,NP)、双酚A(bisphenolA ,BisA)和邻苯二甲酸二丁酯 (dibutylphthalate ,DBP)对乳腺癌细胞株MCF 7凋亡的影响 ,探讨环境雌激素促进MCF 7细胞增殖的生物学机制。 [方法 ]将在DMEM培养液 (含 10 %小牛血清 )中的MCF 7细胞采用开放式单层贴壁培养 ,加受试物前 5d将培养细胞用PBS洗涤后改为在无酚红DMEM(含 5 %经活性碳 葡聚糖苷处理的胎牛血清 ,CDT FBS)中培养连续 5d ,其目的是耗尽细胞内储存的雌激素。实验设溶剂对照组、雌激素对照组、抗雌激素 (它莫西芬 )对照组及三个实验组 ,采用流式细胞术、DNA片段凝胶电泳和细胞苏木素染色 (HE) ,观察环境雌激素对雌激素耗尽所诱导的细胞凋亡作用的影响。 [结果 ] 3 2× 10 -6mol/LNP和 3 2×10 -5mol/LBisA对MCF 7细胞处理 72h ,与对照组相比 ,流式细胞仪分析结果表明 ,二倍体细胞 (G1期细胞 )明显增加 ,亚二倍体细胞峰 (即细胞凋亡率 )消失 ,DNA凋亡片段凝胶电泳不显示典型的凋亡DNA片段梯带 ,细胞苏木素染色结果也显示凋亡细胞明显减少。 [结论 ]与溶剂对照组相比 ,NP和BisA均能够抑制MCF 7细胞的凋亡作用 ,而 3 2× 10 -4mol/LDBP对细胞凋亡的影响作用不明显。这一结果提示 ,该类物质有可能是通过抑制细胞凋亡而?

玉米赤霉烯酮对MCF-7细胞肿瘤相关基因表达的影响

目的观察真菌类环境雌激素玉米赤霉烯酮(zearalenone,ZEA)对雌激素依赖性乳腺癌细胞MCF-7肿瘤相关基因表达的影响,初步探讨ZEA与乳腺癌发生、发展的关系及其作用机制。方法在同等条件下,溶剂对照组(ethanol,EtOH)和32×10-9mol/L ZEA对MCF-7细胞分别处理72h,收集细胞并提取细胞总mRNA,用Cy5和Cy3两种不同荧光染料通过逆转录反应将mRNA分别标记成两种探针,并与载有一组靶基因的人肿瘤相关基因表达谱芯片进行杂交,经计算机扫描分析得出这些基因在经ZEA处理前后的表达差异。结果筛选出包括与细胞增殖、细胞凋亡、细胞转化、应激反应、肿瘤逃逸等相关表达差异的基因共15条,其中4条基因下调(主要是抑癌基因和调节细胞增殖、凋亡相关的基因等),11条基因上调(主要是热休克蛋白基因、雌激素反应基因、内源性逆转录病毒基因、HPK/GCK激酶基因及与肿瘤发生、发展密切相关的原癌基因等)。结论ZEA上调基因数目多于下调基因数目,且上调基因多数是促进细胞增殖的基因,还有两个是与肿瘤发生有关的基因,提示ZEA对相关肿瘤的发生发展起着促进作用并具有一定的致癌性。

紫龙金对人乳腺癌细胞系MCF-7增殖及凋亡的影响

目的观察复方中药紫龙金对人乳腺癌细胞系MCF-7增殖的抑制作用及对其凋亡的诱导作用,探讨紫龙金治疗乳腺癌的作用机制。方法依据培养液紫龙金浓度的差异,实验共设4组:(1)对照组:不加紫龙金干预的1640培养液;(2)紫龙金低浓度组:1.5 mg生药/mL紫龙金培养液;(3)紫龙金中浓度组:3 mg生药/mL紫龙金培养液;(4)紫龙金高浓度组:6 mg生药/mL紫龙金培养液。采用细胞计数法绘制生长曲线及四甲基偶氮唑蓝(MTT)比色法检测不同浓度紫龙金对MCF-7细胞增殖能力的影响,并应用流式细胞术、Hoechst 33342核染色法及DNA梯度形成法测定紫龙金诱导凋亡的作用。结果(1)与对照组比较,紫龙金各剂量组的细胞计数在各时间点(24、48、72、96、120、144 h)明显减少,其差异均有统计学意义(P<0.05);紫龙金各剂量组间的生长抑制率差异除低、中浓度组间在24、72 h无统计学意义外(P>0.05),各剂量组间两两比较在不同时间点(24、48、72、96、120、144 h),其差异均有统计学意义(P<0.05)。紫龙金对MCF-7细胞的增殖抑制作用呈时间依赖性和剂量依赖性;(2)紫龙金使细胞阻滞在G_0/G_1期;(3)中、高浓度紫龙金诱导MCF-7细胞凋亡,并形成DNA ladder。结论紫龙金能抑制人乳腺癌细胞MCF-7细胞增殖,并诱导细胞凋亡,从而起到抗肿瘤的作用。